Phase II Trial of CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome
Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether processing blood stem cell transplants using an
investigational device (the CliniMACS system) results in fewer complications for patients who
undergo transplant to treat a blood malignancy (cancer) or blood disorder.
The CliniMACS system will be used to remove immune T-cells from the transplant donor's blood.
Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that
can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's
cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or
reducing the severity of GVHD.